Skip to content

Released Nov 2, 2021, before the open

10-Q filed Nov 2, 2021, 33 days after period end · 0000917520-21-000049

Q3 2021 · 10-Q
Revenue$386.86M+4.5% vs Q3 2020−0.8% vs Q2 2021
Net Income$43.23M+33.7% vs Q3 2020+23.3% vs Q2 2021
EPS Diluted$0.51+34.2% vs Q3 2020+24.4% vs Q2 2021
Operating Income$56,439,000−1.9%
Operating Cash Flowderived$82,779,000+18.9%
Free Cash Flowderived$75,493,000+20.0%
Margins · derived
Operating margin14.6%−1.0 pt vs Q3 2020
Net margin11.2%+2.4 pt vs Q3 2020

What the release said

The release

Same quarter

MetricQ3 2021Q3 2020Q3 2019Q3 2018
Revenue$386.86M$370.23M$379.10M$365.85M
Net Income$43.23M$32.34M-$27.61M$13.30M
EPS Diluted$0.51$0.38-$0.32$0.15

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR